

Report From Agency

**STATE OF WISCONSIN
PHARMACY EXAMINING BOARD**

**IN THE MATTER OF RULEMAKING :
PROCEEDINGS BEFORE THE : REPORT TO THE LEGISLATURE
PHARMACY EXAMINING BOARD : CR 21-074**

I. THE PROPOSED RULE:

The proposed rule, including the analysis and text, is attached.

II. REFERENCE TO APPLICABLE FORMS: N/A

III. FISCAL ESTIMATE AND EIA: The Fiscal Estimate and EIA is attached.

IV. DETAILED STATEMENT EXPLAINING THE BASIS AND PURPOSE OF THE PROPOSED RULE, INCLUDING HOW THE PROPOSED RULE ADVANCES RELEVANT STATUTORY GOALS OR PURPOSES:

The Pharmacy Examining Board identified the following rules in its 2019 report filed with the Joint Committee for Review of Administrative Rules pursuant to s. 227.29, Stats.

- Phar 5.02 is revised to delete obsolete or unnecessary provisions to require the notification to the Board regarding name or address change to be submitted in writing.
- Phar 6.04 is revised to delete economically burdensome requirements and requirements which do not correspond with the evolving types of pharmacies.
- Phar 7.04 (3) is revised to correct a typographical error occurring in CR 19-145 related to which should refer to Schedule III – V drugs instead of Schedule III – IV drugs. The omission of Schedule V creates inconsistency with the federal law and confusion for pharmacists.
- Ch. Phar 11 is repealed as it is duplicative and unnecessary.
- Phar 12.04 is revised as the federal standards referenced have been superseded.

V. SUMMARY OF PUBLIC COMMENTS AND THE BOARD’S RESPONSES, EXPLANATION OF MODIFICATIONS TO PROPOSED RULES PROMPTED BY PUBLIC COMMENTS:

The Pharmacy Examining Board held a public hearing on December 2, 2021. No public comments were received.

VI. RESPONSE TO LEGISLATIVE COUNCIL STAFF RECOMMENDATIONS:

All of the recommendations suggested in the Clearinghouse Report have been accepted in whole.

VII. REPORT FROM THE SBRRB AND FINAL REGULATORY FLEXIBILITY ANALYSIS: N/A